20 March, 2009 -- Pronova BioPharma ASA today announces that it and its U.S. marketing partner GlaxoSmithKline Inc. have received a Paragraph IV Notice Letter dated March 17 2009 from Par Pharmaceutical Inc. advising that Par has submitted an ANDA to the US FDA for approval to market a generic version of Lovaza (omega-3-acid ethyl esters).
The details can be read here.
No comments:
Post a Comment